Palisade Bio Strengthens IBD Pipeline with Precision Medicine Expert
Event summary
- Palisade Bio appointed Bram Verstockt, MD, PhD, to its Clinical Advisory Board on February 17, 2026.
- Verstockt is an IBD staff physician and professor at University Hospitals Leuven and KU Leuven, Belgium.
- Palisade plans to submit an IND application for a Phase 2 study of PALI-2108 in ulcerative colitis in the first half of 2026.
- PALI-2108 is a once-daily, oral PDE4 inhibitor prodrug designed for targeted delivery to the terminal ileum and colon.
The big picture
Palisade Bio's appointment of Bram Verstockt underscores the growing emphasis on precision medicine in IBD drug development. The move comes as the company prepares to advance its lead candidate, PALI-2108, into Phase 2 trials, leveraging Verstockt's expertise in advanced imaging and biomarker integration to optimize patient selection and endpoint strategies. This strategic enhancement positions Palisade to compete in a crowded IBD market by differentiating its approach through targeted, non-invasive disease assessment.
What we're watching
- Clinical Strategy
- How Verstockt's expertise in precision medicine and non-invasive disease assessment will shape PALI-2108's Phase 2 trial design.
- Regulatory Timeline
- Whether Palisade can meet its target for IND submission in the first half of 2026.
- Therapeutic Differentiation
- The pace at which Palisade can demonstrate the clinical benefit of targeted PDE4 inhibition in UC and FSCD.
Related topics